Tripep AB (publ) appoints Remium Securities as its liquidity provider

Tripep AB (publ) appoints Remium Securities as its liquidity provider Tripep AB has appointed Remium Securities as liquidity provider for its share, which is listed on the O-list of Stockholmsbörsen (the Stockholm Stock Exchange). The purpose is to promote the liquidity in the share within the framework of Stockholmsbörsen's system for liquidity providers. The undertaking takes effect on October 15, 2004. For more information, please contact: Anders Vahlne, CEO and Head of Research Phone +46 (0)8-5858 1313, mobile +46 (0)709-28 05 28 E-mail: Or Björn Garat, Remium Securities +46 (0)8-454 32 91 Tripep is a biotech research company that develops and commercialises candidate drugs based on patented technologies: - clinical development of a HIV-inhibiting drug, - preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, - the RAS® and Ribacine technology platforms, and - a general influenza vaccine in a joint participation with VLP Biotech Inc More details on Tripep's technologies are available at its Website: ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download:

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit:

Documents & Links